Beijing, China – Patients with lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), often undergo progressive kidney damage, with approximately 20% of these patients advancing to end-stage renal disease. The current therapeutic landscape for LN, dominated by glucocorticoids and immunosuppressants, is limited by suboptimal response rates, the...
treatment News
BRISBANE, Calif. — ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational therapy for Charcot-Marie-Tooth disease (CMT). ReviR is preparing to launch a Phase 1 clinical...
CUPERTINO, Calif. — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced European Patent 3749324 has been granted by the European Patent...
CUPERTINO, Calif. — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024...
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom – Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class...
Seoul, South Korea – Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as bladder removal followed by artificial bladder implantation or the use of a urine pouch,...
Edmonton, Alberta – A new case report published in the peer-reviewed OMICS: A Journal of Integrative Biology describes how longitudinal multi-omics monitoring (LMOM) helped to detect a precancerous pancreatic tumor and led to a successful surgical intervention. Click here to read the article. The patient had undergone annual blood-based LMOM, in which 143 endogenous...
By Raffaele Pereno STOCKHOLM, Sweden – Aegle Therapeutics, a clinical-stage biopharmaceutical company, is pioneering the use of extracellular vesicle (EV) therapies derived from mesenchymal stem cells (MSCs) to treat rare and severe immuno-dermatological diseases. During Biotech Showcase 2025, Aegle presented its lead product, AGLE-102™, as a first-in-class therapy for Dystrophic...
Houston, Texas – A researcher at the University of Houston College of Pharmacy Drug Discovery Institute is working to revolutionize treatment regimens for triple-negative breast cancer (TNBC) by proving that nebivolol, an FDA-approved drug for high blood pressure, is effective in treating it. Meghana Trivedi, professor of Pharmacy and Pharmacology,...
CHAPEL HILL, North Carolina – At all dose levels, revumenib (Revuforj) plus azacitidine (Vidaza) and venetoclax (Venclexta) showed safety and feasibility for patients who are newly diagnosed and older with acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangement (KMT2Ar), according to findings from the phase 3 VIALE-A trial (NCT02993523) presented at...